Due to demographics, strong demand, and other factors, the diabetes management products market-including blood glucose monitoring systems, insulin injection devices and insulin pumps, insulin therapies and oral and injectable diabetes drugs-has become one of the largest medical device and pharmaceutical markets in the U.S., totaling more than $15 billion. As the population of diabetics continues to increase, the market is expected to continue to grow at a double-digit rate over the next five years, reaching nearly $28 billion by 2013.
Monitoring glucose levels is critical for the management of diabetes and new and improved portable, less costly, easy-to-use, accurate and virtually painless blood glucose monitoring systems are now available. In addition, new and improved insulin pens are enabling less painful and burdensome daily injection of insulin, helping to spur insulin therapy sales.
In the blood-glucose lowering treatment area, several new drugs, such as Byetta and Januvia have exhibited good safety and efficacy profiles and have reached blockbuster status over the last few years, despite the economic troubles in the U.S. and worldwide. In addition, a substantial number of emerging diabetes drugs are under clinical study by dozens of startup companies and large pharmaceutical companies; with several expected to enter the U.S. market over the next few years. Next-generation diabetes drug therapies are promising to addressing the strong need for safer, long-term blood glucose control, used as monotherapies or in combination with insulin or other oral diabetes drug therapies.
This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. diabetes products market. Product areas include: self-testing blood glucose monitoring systems, continuous blood glucose monitoring systems, insulin therapies, insulin injection devices, insulin pumps, injectable/oral diabetes drugs, and emerging diabetes drugs and technologies, including pancreatic islet cell transplantation.
EXECUTIVE SUMMARY i. Types of Diabetes ii. Diagnosis iii. Management and Treatment iv. Total Diabetes Management Products Market v. Methodology Exhibit ES-1: 2007, Selected Diabetes Statistics Exhibit ES-2: Diagnosis of Diabetes and Pre-Diabetes Exhibit ES-3: Diabetes Management Products, Combined Market Forecast, 2008-2013 Exhibit ES-4: 2013, Diabetes Management Products, Estimated Share of Sales, by Segment 1. CLINICAL OVERVIEW 1.1 Types of Diabetes 1.2 Diagnosis 1.3 Management and Treatment Exhibit 1-1: 2007, Selected Diabetes Statistics Exhibit 1-2: Diagnosis of Diabetes and Pre-Diabetes Exhibit 1-3: Diabetes Complications 2. BLOOD GLUCOSE MONITORING SYSTEMS 2.1 Glucose Monitoring Systems 2.1.1 Abbott Laboratories 2.1.2 Bayer HealthCare/Bayer 2.1.3 Home Diagnostics 2.1.4 LifeScan/Johnson & Johnson 2.1.5 Roche Diagnostics/F. Hoffmann-La Roche 2.1.6 Others 2.2 Continuous Glucose Monitoring Systems 2.2.1 Abbott Laboratories 2.2.2 DexCom 2.2.3 Medtronic 2.3 Lancing Devices 2.3.1 Abbott Laboratories 2.3.2 Bayer HealthCare/Bayer 2.3.3 Home Diagnostics 2.3.4 LifeScan/Johnson & Johnson 2.3.5 Roche Diagnostics/F. Hoffmann-La Roche 2.3.6 Others 2.4 Glucose Monitoring Systems under Development 2.4.1 Echo Therapeutics 2.4.2 Epinex Diagnostics 2.4.3 Sensors for Medicine and Science 2.4.4 Solianis Monitoring 2.4.5 Others 2.5 Market Analysis 2.6 Competitive Analysis Exhibit 2-1: 2009, Selected Blood Glucose Monitoring Systems Exhibit 2-2: Abbott Laboratories' FreeStyle and Precision Xtra Blood Glucose Monitoring Systems Exhibit 2-3: Bayer HealthCare's Breeze2 and Contour Blood Glucose Meters Exhibit 2-4: Home Diagnostics' TRUE2go and TRUEresult Blood Glucose Meters Exhibit 2-5: LifeScan's OneTouch UltraMini Blood Glucose Meter Exhibit 2-6: LifeScan's OneTouch UltraSmart Blood Glucose Meter Exhibit 2-7: LifeScan's OneTouch UltraLink and Medtronic's MiniMed Paradigm REAL-Time Blood Glucose Monitoring Systems Exhibit 2-8: Roche Diagnostics' ACCU-CHEK Compact Plus Blood Glucose Meter Exhibit 2-9: Roche Diagnostics' ACCU-CHEK Aviva and Advantage Blood Glucose Meters Exhibit 2-10: AKRAY USA's PocketChem EZ and GLUCOCARD Blood Glucose Meters Exhibit 2-11: The ReliOn Ultima Blood Glucose Monitoring System Exhibit 2-12: 2009, Selected Continuous Glucose Monitoring Systems Exhibit 2-13: Abbott Laboratories' FreeStyle Navigator Continuous Blood Glucose Monitoring System Exhibit 2-14: DexCom's SEVEN PLUS Continuous Blood Glucose Monitoring System Exhibit 2-15: Medtronic's Guardian REAL-Time Continuous Blood Glucose Monitoring System Exhibit 2-16: 2009, Selected Lancing Devices Exhibit 2-17: Bayer HealthCare's MICROLET2 and MICROLET VACULANCE Lancing Devices Exhibit 2-18: Home Diagnostics' Gentle Draw Lancing Device Exhibit 2-19: LifeScan's OneTouch Lancing Devices Exhibit 2-20: 2009, Selected Glucose Monitoring Technologies under Development Exhibit 2-21: Echo Therapeutics' Symphony Transdermal Continuous Glucose Monitoring System Exhibit 2-22: Epinex Diagnostics' G1A Rapid Diabetes Monitoring Index Test Prototype Exhibit 2-23: Sensors for Medicine and Science's SMSI Glucose Sensor Exhibit 2-24: Blood Glucose Monitoring Systems, Market Forecast, 2008-2013 Exhibit 2-25: 2008, Blood Glucose Monitoring Systems Market, Share by Supplier 3. DIABETES DRUG THERAPY 3.1 Insulin Therapy 3.1.1 Eli Lilly 188.8.131.52 Humalog 184.108.40.206 Humulin 3.1.2 Novo Nordisk 220.127.116.11 Levemir 18.104.22.168 NovoLog 22.214.171.124 NovoLog Mix 70/30 3.1.3 Sanofi-aventis 126.96.36.199 Apidra 188.8.131.52 Lantus 3.2 Injectable Diabetes Drugs 3.2.1 Amylin Pharmaceuticals and Eli Lilly 184.108.40.206 Byetta 220.127.116.11 Symlin 3.3 Oral Diabetes Drugs 3.3.1 Bayer HealthCare/Bayer 18.104.22.168 Glucobay 3.3.2 Bristol-Myers Squibb 22.214.171.124 Glucophage 126.96.36.199 Glucovance 3.3.3 GlaxoSmithKline 188.8.131.52 Avandia 184.108.40.206 Avandamet 220.127.116.11 Avandaryl 3.3.4 Merck 18.104.22.168 Januvia 22.214.171.124 Janumet 3.3.5 Novartis 126.96.36.199 Starlix 3.3.6 Novo Nordisk 188.8.131.52 Prandin 3.3.7 Pfizer 184.108.40.206 Glucotrol 220.127.116.11 Glyset 3.3.8 Sanofi-aventis 18.104.22.168 Amaryl 3.3.9 Takeda Pharmaceuticals North America/ Takeda Pharmaceutical Company 22.214.171.124 Actos 3.4 Generic Diabetes Drugs 3.5 Diabetes Drugs under Development 3.5.1 Oral and Sublingual Insulin 3.6 Aborted Diabetes Drugs 3.7 Market Analysis 3.7.1 Insulin Therapy Products 126.96.36.199 Market Forecast 188.8.131.52 Competitive Analysis 3.7.2 Injectable and Oral Diabetes Drug Therapy 184.108.40.206 Market Forecast 220.127.116.11 Competitive Analysis Exhibit 3-1: 2009, Selected Diabetes Drugs Exhibit 3-2: 2009, Selected Types of Insulin Exhibit 3-3: Eli Lilly's Humulin Insulin Product Line Exhibit 3-4: Byetta's Effects on Blood Glucose Exhibit 3-5: Symlin's Mechanisms of Action Exhibit 3-6: The SymlinPen 120 Injector Device Exhibit 3-7: Januvia's Mechanism of Action Exhibit 3-8: 2009, Selected Diabetes Drugs in Late-Stage Development Exhibit 3-9: Diabetes Drugs under Development Exhibit 3-10: Insulin Therapy Products, Market Forecast, 2008-2013 Exhibit 3-11: 2008, Insulin Therapy Products Market, Share by Supplier Exhibit 3-12: Injectable and Oral Diabetes Drug Therapy Products, Market Forecast, 2008-2013 Exhibit 3-13: 2008, Injectable and Oral Diabetes Drug Therapy Products Market, Share by Supplier 4. INSULIN DELIVERY DEVICES 4.1 Insulin Syringes 4.1.1 Abbott Laboratories 4.1.2 BD 4.2 Insulin Pens 4.2.1 Eli Lilly 4.2.2 Novo Nordisk 4.2.3 sanofi-aventis 4.2.4 Owen Mumford 4.3 External Insulin Pump Systems 4.3.1 Animas/Johnson & Johnson 4.3.2 Smiths Medical/Smiths Group 4.3.3 Insulet 4.3.4 Medtronic 4.3.5 Roche Diagnostics/F. Hoffmann-La Roche 4.3.6 Others 4.4 Insulin Jet Injectors 4.5 Market Analysis 4.5.1 External Insulin Pump Systems 18.104.22.168 Market Forecast 22.214.171.124 Competitive Analysis 4.5.2 Insulin Pens and Syringes 126.96.36.199 Market Forecast 188.8.131.52 Competitive Analysis Exhibit 4-1: 2009, Selected Insulin Syringes Exhibit 4-2: Abbott Laboratories' Precision Sure-Dose Insulin Syringe Exhibit 4-3: The BD Ultra-Fine Insulin Syringe Exhibit 4-4: BD's Safety-Engineered Insulin Syringes Exhibit 4-5: BD's Ultra-Fine Insulin Pen Needles Exhibit 4-6: 2009, Selected Insulin Pens Exhibit 4-7: Eli Lilly's Line of Prefilled Insulin Pens Exhibit 4-8: Eli Lilly's HumaPen MEMOIR and LUXURA HD Insulin Pens Exhibit 4-9: Novo Nordisk's FlexPen Insulin Pens Exhibit 4-10: Novo Nordisk's NovoPen 4 Insulin Pens Exhibit 4-11: Sanofi-aventis' Lantus SoloStar Insulin Pen Exhibit 4-12: Owen Mumford's Autopen Insulin Pen Exhibit 4-13: Diagram of External Insulin Pump Therapy Exhibit 4-14: 2009, Selected External Insulin Pump Systems Exhibit 4-15: Animas' OneTouch Ping Glucose Management System Exhibit 4-16: Smiths Medical's Deltec Cozmo Insulin Pump Exhibit 4-17: Insulet's OmniPod Insulin Management System Exhibit 4-18: Medtronic's MiniMed Paradigm Insulin Pump Exhibit 4-19: Roche Diagnostics' ACCU-CHEK Spirit Insulin Pump Exhibit 4-20: Nipro Diabetes Systems' Amigo Insulin Pump Exhibit 4-21: Activa Brand Products' AvantaJet Insulin Injector Exhibit 4-22: External Insulin Pump Systems, Market Forecast, 2008-2013 Exhibit 4-23: 2008, External Insulin Pump Systems Market, Share by Supplier Exhibit 4-24: Insulin Pens and Syringes, Market Forecast, 2008-2013 Exhibit 4-25: 2008, Insulin Pens Market, Share by Supplier Exhibit 4-26: 2008, Insulin Syringes Market, Share by Supplier 5. EMERGING TECHNOLOGIES 5.1 Pancreatic Islet Cell Transplantation 5.1.1 Cerco Medical 5.1.2 Geron 5.1.3 MicroIslet 5.1.4 Novocell 5.1.5 Opexa Therapeutics 5.1.6 Senesco Technologies 5.1.7 Sernova 5.2 Umbilical Cord Blood Transfusion Exhibit 5-1: Diagram of the Pancreas and Islets of Langerhans Exhibit 5-2: Pancreatic Islet Transplantation Procedure Exhibit 5-3: Edmonton Protocol and Research Development Exhibit 5-4: 2009, Selected Emerging Stem Cell and Pancreatic Islet Cell Transplantation Technologies Exhibit 5-5: Cerco Medical's Definition of a Bio-Artificial Pancreas and Islet Sheet Technology Exhibit 5-6: MicroIslet's Encapsulated Porcine Islet Technology Exhibit 5-7: Opexa Therapeutics' Monocyte-Derived Stem Cell Technology 6. COMPANY PROFILES 6.1 Abbott Laboratories 6.2 Amylin Pharmaceuticals, Inc. 6.3 Bayer HealthCare AG/Bayer AG 6.4 Home Diagnostics, Inc. 6.5 Johnson & Johnson 6.6 Eli Lilly and Company 6.7 Medtronic, Inc. 6.8 Merck & Company, Inc. 6.9 Novo Nordisk AS 6.10 Roche Diagnostics/F. Hoffmann-La Roche LTD 6.11 sanofi-aventis 6.12 Teva Pharmaceutical Industries LTD 6.13 Takeda Pharmaceuticals North America/Takeda Pharmaceutical Company APPENDIX: COMPANY LISTING